Dinesh Patel - Protagonist Therapeutics President CEO, Director
| PTGX Stock | USD 44.95 0.12 0.27% |
CEO
Dr. Dinesh V. Patel, Ph.D. serves as President, Chief Executive Officer, Director of the Company. He has served as a member of the Companys board of directors and as the Companys President and Chief Executive Officer since December 2008. Dr. Patel has more than 30 years of executive, entrepreneurial and scientific experience spanning the pharmaceutical, biotechnology and biopharmaceutical industries. Prior to joining the Company, Dr. Patel served from 2006 to 2008 as the President and Chief Executive Officer of Arte Therapeutics, a privately held company focused on the development of drugs for metabolic syndrome. Prior to that, he was the President and Chief Executive Officer of Miikana Therapeutics, an oncologybased company, from 2003 until it was acquired by Entremed in 2005. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor, from 1996 to 2003, most recently as Senior Vice President of Drug Discovery and Licensing. Prior to Vicuron, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax, from 1993 to 1996. Dr. Patel was a medicinal chemist at BristolMyers Squibb from 1985 to 1993 since 2019.
| Age | 67 |
| Tenure | 5 years |
| Professional Marks | Ph.D |
| Address | 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160 |
| Phone | 510 474 0170 |
| Web | https://www.protagonist-inc.com |
Dinesh Patel Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dinesh Patel against Protagonist Therapeutics stock is an integral part of due diligence when investing in Protagonist Therapeutics. Dinesh Patel insider activity provides valuable insight into whether Protagonist Therapeutics is net buyers or sellers over its current business cycle. Note, Protagonist Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Protagonist Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dinesh Patel 2 days ago Disposition of 21480 shares by Dinesh Patel of Protagonist Therapeutics at 46.25 subject to Rule 16b-3 | ||
Dinesh Patel 3 days ago Disposition of 1727 shares by Dinesh Patel of Protagonist Therapeutics at 21.58 subject to Rule 16b-3 | ||
Dinesh Patel over three months ago Disposition of 1000 shares by Dinesh Patel of Protagonist Therapeutics subject to Rule 16b-3 | ||
Dinesh Patel over three months ago Disposition of 35000 shares by Dinesh Patel of Protagonist Therapeutics at 35.19 subject to Rule 16b-3 |
Protagonist Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.1996 % which means that it generated a profit of $0.1996 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4097 %, meaning that it created $0.4097 on every $100 dollars invested by stockholders. Protagonist Therapeutics' management efficiency ratios could be used to measure how well Protagonist Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.23 in 2024. Return On Capital Employed is likely to drop to -0.29 in 2024. Total Assets is likely to drop to about 204.1 M in 2024. Net Tangible Assets is likely to drop to about 141.3 M in 2024Similar Executives
| Found 12 records | CEO Age | ||
| David PharmD | Verona Pharma PLC | 60 | |
| Sarah Boyce | Avidity Biosciences | 52 | |
| Daniel MBA | Acumen Pharmaceuticals | 54 | |
| John Houston | Arvinas | 64 | |
| Amy MBA | Terns Pharmaceuticals | 54 | |
| Mark Goldsmith | Revolution Medicines | 62 | |
| Raju Mohan | Ventyx Biosciences | 66 | |
| Robert Coffin | Replimune Group | 59 | |
| Malte MD | Hookipa Pharma | 62 | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Paula Ragan | X4 Pharmaceuticals | 54 | |
| Andrew MD | Akero Therapeutics | 57 | |
Management Performance
Protagonist Therapeutics Leadership Team
Elected by the shareholders, the Protagonist Therapeutics' board of directors comprises two types of representatives: Protagonist Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protagonist. The board's role is to monitor Protagonist Therapeutics' management team and ensure that shareholders' interests are well served. Protagonist Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protagonist Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mohammad Masjedizadeh, Executive Officer | ||
| Abha Bommireddi, Executive Management | ||
| Matthew JD, Executive Counsel | ||
| Ashok Bhandari, Vice President - Chemistry | ||
| Matthew Gosling, Executive Counsel | ||
| Richard Shames, Chief Medical Officer | ||
| Dinesh Patel, President CEO, Director | ||
| David Liu, Chief Scientific Officer, Head of Research & Development | ||
| Carena Spivey, Senior Resources | ||
| Suneel Gupta, Executive Vice President of Clinical Operations and Clinical Pharmacology | ||
| Mark Smythe, Vice President -Technology & Alliances | ||
| Scott MD, Executive Gastroenterology | ||
| FACP MD, Chief Officer | ||
| Carter King, Executive Development | ||
| Asif Ali, Executive Officer |
Protagonist Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protagonist Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.41 | ||||
| Return On Asset | 0.2 | ||||
| Profit Margin | 0.53 % | ||||
| Operating Margin | (8.87) % | ||||
| Current Valuation | 2.22 B | ||||
| Shares Outstanding | 59.6 M | ||||
| Shares Owned By Insiders | 1.17 % | ||||
| Shares Owned By Institutions | 98.83 % | ||||
| Number Of Shares Shorted | 3.3 M | ||||
| Price To Earning | (4.81) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.